Biohaven Pharma (BHVN) Misses Q3 EPS by 10c

Biohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($1.44), $0.10 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $0.

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c